Carlsbad, CA – According to filings with the U.S. Securities and Exchange Commission, Curate Biosciences fka GPB Scientific is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mike Grisham played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Curate Biosciences fka GPB Scientific
Curate Biosciences, formerly GPB Scientific, enables virtually lossless cell processing, transforming the outcomes and economics of cell therapy manufacturing. GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company’s advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the systems upcoming commercial introduction. Anticipating the commercial launch, the company is changing its name to Curate Biosciences to better communicate its benefits to the gene and cell therapy industry.

To learn more about Curate Biosciences fka GPB Scientific, visit http://www.curatebio.com/

Contact:
Mike Grisham, Chief Executive Officer
442-291-2110
mike.grisham@curatebio.com
https://www.linkedin.com/in/mike-grisham-8461113/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved